Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835553 | 0.88 | GRM2 (0.44) | ALOX5APFEN1GRM2AAK1NPC1 | |
| SCHEMBL25835684 | 0.83 | IDO1 (0.41) | ALPLAAK1MAPTTGFBR1ACVR1B | |
| SCHEMBL25835681 | 0.80 | GRM2 (0.45) | GRM2L3MBTL1 | |
| SCHEMBL26192317 | 0.76 | L3MBTL1 (0.40) | GRM2MAPTL3MBTL1 | |
| SCHEMBL26193310 | 0.75 | GRM2 (0.42) | ALOX5APFEN1GRM2AAK1L3MBTL1 | |
| SCHEMBL5857430 | 0.74 | KCNA5 (0.52) | L3MBTL1 | |
| SCHEMBL25836843 | 0.74 | GRM2 (0.43) | ALOX5APFEN1GRM2AAK1NPC1 | |
| SCHEMBL30510038 | 0.74 | GRM2 (0.43) | ALOX5APFEN1GRM2AAK1NPC1 | |
| SCHEMBL12791296 | 0.74 | P2RX7 (0.46) | GRM2P2RX7 | |
| SCHEMBL30509985 | 0.72 | NTRK1 (0.46) | ALOX5APFEN1GRM2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | ALOX5AP 3911/4885FEN1 1429/4885ALPL 2975/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | ALOX5AP 3911/4885FEN1 1429/4885ALPL 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.